Oberoesterreichische Gesundheitsholding GmbH — Clinical Trial Site

14 Registered trials

4 Currently recruiting

Organisation

Oberoesterreichische Gesundheitsholding GmbH

Location

Steyr, Austria

Identifier

ORG-100024827

Address

Sierninger Straße 170, 4400, Austria

Departments

1. Med. Abteilung
2. Med. Abteilung
Department of Cardiology, Nephrology and Internal Intensive Care Medicine
Department of Internal Medicine 1
Department of Internal Medicine II
Department of Medicine II
Innere Med.
Innere Medizin II
Innere Medizin II, Onkologie, Gastroenterologie, Angiologie
Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
Internal Medicine I
Neurology

Clinical trials at this site (14)

Search interface

BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended

2022-500897-32-00 Chronic pain due to diabetic polyneuropathy 5 2023-11-02
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended

2022-500898-13-00 Chronic Pain due to traumatic or post-operative periphe 5 2023-11-02
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended

2022-500899-66-00 Chronic pain due to central Neuropathy of any Genesis 5 2023-11-02
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Chronic back pain 5 2023-11-02
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15